Precision BioSciences Inc Cash Flow Conversion Efficiency
Precision BioSciences Inc cash flow conversion efficiency. Based on the latest financial reports, Precision BioSciences Inc (DTIL) has a cash flow conversion efficiency ratio of -0.297x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.44 Million) by net assets ($45.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Precision BioSciences Inc (2016–2025)
Cash flow conversion efficiency of Precision BioSciences Inc from 2016 to 2025. This chart illustrates how Precision BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Precision BioSciences Inc share price for real-time trading data and today's change.
Precision BioSciences Inc Cash Flow Conversion Ratio Explained
Precision BioSciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Precision BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precision BioSciences Inc ranked by their cash flow conversion efficiency. Also see Precision BioSciences Inc (DTIL) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NINtec Systems Limited
NSE:NINSYS
|
0.151x |
|
Landmark Bancorp Inc
NASDAQ:LARK
|
0.020x |
|
Brockhaus Capital Management AG
F:BKHT
|
0.059x |
|
Pioneer Municipal High Income Opportunities Fund Inc
NYSE:MIO
|
-1.549x |
|
Microvast Holdings Inc
NASDAQ:MVST
|
0.009x |
|
Stic Investments Inc
KO:026890
|
0.005x |
|
MPC Münchmeyer Petersen Capital AG
F:MPCK
|
0.058x |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.052x |
Annual Cash Flow Conversion Efficiency for Precision BioSciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Precision BioSciences Inc from 2016 to 2025. Review Precision BioSciences Inc (DTIL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $92.25 Million | $-65.84 Million | -0.714x | +31.13% |
| 2024-12-31 | $56.39 Million | $-58.45 Million | -1.036x | +76.76% |
| 2023-12-31 | $18.86 Million | $-84.11 Million | -4.460x | -489.06% |
| 2022-12-31 | $60.43 Million | $-45.75 Million | -0.757x | -535.97% |
| 2021-12-31 | $91.17 Million | $-10.85 Million | -0.119x | +93.95% |
| 2020-12-31 | $44.42 Million | $-87.39 Million | -1.967x | -269.47% |
| 2019-12-31 | $138.31 Million | $-73.64 Million | -0.532x | +58.87% |
| 2018-12-31 | $39.96 Million | $-51.72 Million | -1.294x | -241.22% |
| 2017-12-31 | $-26.37 Million | $-24.17 Million | 0.917x | +104.72% |
| 2016-12-31 | $-4.75 Million | $92.27 Million | -19.430x | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more